Cady R K, Gutterman D, Saiers J A, Beach M E
Headache Care Center, Springfield, MO 65804, USA.
Cephalalgia. 1997 Aug;17(5):588-90. doi: 10.1046/j.1468-2982.1997.1705588.x.
In a long-term efficacy and safety study, 424 patients were treated with sumatriptan (6 mg sc) for 1,904 migraine attacks. The patients were diagnosed with migraine based on IHS criteria but individual migraine attacks treated in the study were physician diagnosed; not necessarily required to meet IHS criteria. A re-analysis of the treatment response to open label sumatriptan (6 mg sc) indicated that 43 patients had treated at least one migraine that fulfilled IHS criteria for tension-type headache. Analysis of this population revealed they treated 232 headaches. Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache). Of the 114 migraines, a positive response to sumatriptan occurred in 109 (96%) cases; of the 76 tension-types, 73 responded to sumatriptan (97%); of the 42 non-IHS migraine, 40 (95%) responded to sumatriptan. An equivalent response to sumatriptan among three diagnostic groups of headache supports the concept of a common biologic mechanism involving 5HT1 receptors that spans a range of clinical presentations.
在一项长期疗效和安全性研究中，424例患者接受舒马曲坦（皮下注射6毫克）治疗1904次偏头痛发作。这些患者根据国际头痛协会（IHS）标准被诊断为偏头痛，但该研究中接受治疗的个体偏头痛发作由医生诊断；不一定要求符合IHS标准。对开放标签舒马曲坦（皮下注射6毫克）治疗反应的重新分析表明，43例患者至少治疗过一次符合IHS紧张型头痛标准的偏头痛。对这一人群的分析显示，他们共治疗了232次头痛。在这些头痛中，根据IHS标准，114次被归类为偏头痛；76次为紧张型；42次为非IHS偏头痛（无法归类为IHS偏头痛或IHS紧张型头痛）。在114次偏头痛中，舒马曲坦产生阳性反应的有109例（96%）；在76次紧张型头痛中，73次对舒马曲坦有反应（97%）；在42次非IHS偏头痛中，40次（95%）对舒马曲坦有反应。头痛的三个诊断组对舒马曲坦的等效反应支持了涉及5HT1受体的共同生物学机制的概念，该机制跨越一系列临床表现。
